Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of midazolam and ondansetron is used primarily for preventing postoperative nausea and vomiting (PONV), particularly in surgical settings. Studies have shown that this combination is more effective than using either drug alone. Midazolam is a benzodiazepine with sedative, anxiolytic, and amnestic properties, while ondansetron is a serotonin 5-HT3 receptor antagonist that works by blocking serotonin action, which can cause nausea and vomiting. ## Pharmacological Properties Midazolam provides sedation and anxiolysis, making it useful in surgical settings. It's commonly administered before or during diagnostic or therapeutic procedures. Ondansetron specifically targets the mechanisms that cause nausea and vomiting, making it effective for preventing PONV. Research has demonstrated that the combination of midazolam (0.75 mg/kg) with ondansetron (4 mg) is more effective than using either medication alone in preventing PONV after middle ear surgery[1]. Another study showed that midazolam added to patient-controlled analgesia (PCA) using fentanyl was more effective than ondansetron in preventing PONV without adverse effects[4]. ## Clinical Applications The combination is primarily used in: - Prevention of postoperative nausea and vomiting - Sedation before or during surgical procedures - Management of nausea and vomiting in various clinical settings When used together, these medications have shown a synergistic effect in reducing PONV incidence rates, particularly in the immediate postoperative period[4]. ## Safety Considerations There are numerous drug interactions to be aware of when using this combination. According to the search results, there are 806 drugs known to interact with ketamine/midazolam/ondansetron, with 327 major interactions, 450 moderate interactions, and 29 minor interactions[2]. Additionally, there are 16 disease interactions and 4 alcohol/food interactions to consider[2][5]. The combination appears to be physicochemically stable and safe when properly administered[4]. However, careful monitoring is essential due to the potential for sedative effects and other adverse reactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Midazolam + Ondansetron.